Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

181. Cross-sectional study: In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life

Cross-sectional study: In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment and household income influence quality of life | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here In individuals with schizophrenia, duration and severity of mental illness, health status, mutuality, employment

Evidence-Based Nursing (Requires free registration)2013

182. Psychosis and schizophrenia in children and young people: recognition and management

Psychosis and schizophrenia in children and young people: recognition and management Psy Psychosis and schizophrenia in children chosis and schizophrenia in children and y and young people: recognition and oung people: recognition and management management Clinical guideline Published: 23 January 2013 nice.org.uk/guidance/cg155 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility (...) and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Psychosis and schizophrenia in children and young people: recognition and management (CG155) © NICE 2018. All rights reserved. Subject

National Institute for Health and Clinical Excellence - Clinical Guidelines2013

183. Schizophrenia: omega-3 fatty acid medicines

Schizophrenia: omega-3 fatty acid medicines Schizophrenia: omega-3 fatty acid medicines Schizophrenia: omega-3 fatty acid medicines Evidence summary Published: 24 September 2013 nice.org.uk/guidance/esuom19 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in September 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date (...) information. Summary The randomised controlled trial (RCT) evidence for using omega-3 fatty acid medicines in people with schizophrenia is limited and the results are not consistent. Regulatory status: Regulatory status: off-label. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 1 of 27Effectiv Effectiveness eness Inconclusive evidence from 8 placebo-controlled RCTs in people with schizophrenia. 4 RCTs show some

National Institute for Health and Clinical Excellence - Advice2013

184. Schizophrenia (revised)

Schizophrenia (revised) AACAP OFFICIAL ACTION Practice Parameter for the Assessment and Treatment of Children and Adolescents With Schizophrenia Jon McClellan, M.D., Saundra Stock, M.D., ANDthe American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI) This Practice Parameter reviews the literature on the assessment and treatment of children and adolescentswithschizophrenia.Early-onsetschizophreniaisdiagnosedusingthesamecriteriaasin (...) sideeffects.Furtherresearchisneededtodevelopmoreeffectiveandsafertreatments. J.Am.Acad. ChildAdolesc.Psychiatry,2013;52(9):976–990. Key Words: schizophrenia, psychosis S chizophreniaportendssubstantialmorbidity and suffering to those af?icted and their families. Schizophrenia spectrum disorders often?rstpresentduringadolescenceandrarelyin childhood.SincethelastPracticeParameterforthe Assessment and Treatment of Children and Adolescents with Schizophrenia was published, 1 knowledge of this topic has increased substan- tially.Thisrevisedversionoftheparameterpresents

American Academy of Child and Adolescent Psychiatry2013

185. Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia

Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia Systematic review of the benefits of physical therapy within a multidisciplinary care approach for people with schizophrenia Vancampfort D, Probst M, Helvik Skjaerven L, Catalan-Matamoros D, Lundvik-Gyllensten A, Gomez-Conesa A, Ijntema R, De Hert M (...) CRD summary The authors cautiously concluded that specific physical therapy interventions resulted in beneficial outcomes for psychiatric symptoms, psychological distress, state anxiety, health-related quality of life and aerobic and muscular fitness. This was a well-conducted review and the authors' conclusions reflect some limitations of the evidence. However, the added value of physical therapy in people with schizophrenia remains unclear. Authors' objectives To evaluate the effectiveness

DARE.2012

186. Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis

Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Time to all-cause treatment discontinuation of olanzapine compared to other antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis Soares (...) antipsychotics for the treatment of schizophrenia in terms of time to all-cause medication discontinuation and all-cause treatment discontinuation rate. Searching MEDLINE, EMBASE, Science Citation Index, The Cochrane Library (Issue 4) and the Cochrane Schizophrenia Group Register were searched from inception to April 2009 for articles in any language. Search terms were reported. Study selection Randomised controlled trials (RCTs) and observational studies that compared olanzapine with any other oral

DARE.2012

187. Flupenthixol versus placebo for schizophrenia.

Flupenthixol versus placebo for schizophrenia. BACKGROUND: Flupenthixol, first made available in the UK in 1965, has been used as a treatment for schizophrenia for decades. OBJECTIVES: To evaluate the absolute clinical effects of flupenthixol for schizophrenia in comparison with placebo. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (August 2011), inspected references of all included or excluded studies for further trials, and contacted authors of trials (...) for additional information. SELECTION CRITERIA: All randomised controlled trials (RCTs) that compared flupenthixol with placebo for adults with schizophrenia or related disorders by any means of diagnosis. Primary outcomes of interest were clinically important change in global state, mental state and behaviour, and adverse effects. DATA COLLECTION AND ANALYSIS: We extracted data from the one included study, discussed any disagreement, documented decisions and contacted the authors of the included study

Cochrane2012

188. Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia

Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia 22581236 2012 08 31 2013 07 08 2014 11 14 1535-7228 169 7 2012 Jul The American journal of psychiatry Am J Psychiatry Examining transcranial direct-current stimulation (tDCS) as a treatment for hallucinations in schizophrenia. 719-24 10.1176/appi.ajp.2012.11071091 Some 25%–30% of patients with schizophrenia have auditory verbal hallucinations that are refractory to antipsychotic drugs (...) patients with schizophrenia and medication-refractory auditory verbal hallucinations were randomly allocated to receive 20 minutes of active 2-mA tDCS or sham stimulation twice a day on 5 consecutive weekdays. The anode was placed over the left dorsolateral prefrontal cortex and the cathode over the left temporo-parietal cortex. Auditory verbal hallucinations were robustly reduced by tDCS relative to sham stimulation, with a mean diminution of 31% (SD=14; d=1.58, 95% CI=0.76–2.40). The beneficial

EvidenceUpdates2012

189. Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics

Bitopertin for schizophrenia: primary, persistent negative symptoms sub-optimally controlled positive symptoms ? in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics NIHR HSC Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSC. Bitopertin for schizophrenia: primary, persistent negative symptoms; sub-optimally controlled positive symptoms – in combination with antipsychotics. Birmingham: NIHR Horizon Scanning Centre (NIHR HSC). Horizon Scanning Review. 2012 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antipsychotic

Health Technology Assessment (HTA) Database.2012

190. Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia Graham CN, Mauskopf JA, Lawson AH, Ascher-Svanum H, Bruhn D Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective of the study was to assess the cost-effectiveness of olanzapine and ziprasidone in the treatment of schizophrenia in USA. The authors concluded that olanzapine was associated with better health outcomes

NHS Economic Evaluation Database.2012

192. Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE)

Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE) Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE) Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2012

193. Antipsychotic drug treatment for elderly people with late-onset schizophrenia.

Antipsychotic drug treatment for elderly people with late-onset schizophrenia. BACKGROUND: Schizophrenia is usually considered an illness of young adulthood. However, onset after the age of 40 years is reported in 23% of patients hospitalised with schizophrenia. At least 0.1% of the world's elderly population have a diagnosis of late-onset schizophrenia which seems to differ from earlier onset schizophrenia on a variety of counts including response to antipsychotic drugs. OBJECTIVES: To assess (...) the effects of antipsychotic drugs for elderly people with late-onset schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group Trials Register (January 2010) which is based on regular searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected references of all identified studies for further trials. We contacted relevant authors of trials for additional information. SELECTION CRITERIA: All relevant randomised controlled trials that compared antipsychotic drugs with other treatments

Cochrane2012

194. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia

Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia Phanthunane P, Vos T, Whiteford H, Bertram M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of interventions to treat schizophrenia, including typical antipsychotics, generic risperidone, olanzapine, clozapine, and family intervention. The authors concluded that atypical antipsychotics, such as risperidone, at generic prices, were cost-effective compared with typical antipsychotics, and family intervention was a cost-effective

NHS Economic Evaluation Database.2012

195. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials

Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S CRD summary This largely well (...) -conducted review concluded that available evidence suggested a clinically meaningful superiority of intramuscular depot injection compared with oral administration of antipsychotic drugs in outpatients with schizophrenia, but that further research is needed. The authors’ conclusions are appropriately cautious given the suboptimal quality of included trials and limited evidence available. Authors' objectives To compare intramuscular depot injections with oral formulations of antipsychotic drugs in people

DARE.2012

196. Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS)

Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS) 22130748 2011 12 01 2012 01 31 2011 12 01 1472-1465 199 6 2011 Dec The British journal of psychiatry : the journal of mental science Br J Psychiatry Schizophrenia medication adherence in a resource-poor setting: randomised controlled trial of supervised treatment in out-patients for schizophrenia (STOPS). 467-72 10.1192/bjp.bp.110.085340 (...) Most people with schizophrenia in low- and middle-income (LAMI) countries receive minimal formal care, and there are high rates of non-adherence to medication. To evaluate the effectiveness of an intervention that involves a family member in supervising medication administration - supervised treatment in out-patients for schizophrenia (STOPS) - in improving treatment adherence and clinical outcomes. Individuals (n = 110) with schizophrenia or schizoaffective disorders were allocated to STOPS

EvidenceUpdates2012

197. Review: emotion identification deficits are associated with functional impairments in people with schizophrenia

Review: emotion identification deficits are associated with functional impairments in people with schizophrenia Review: emotion identification deficits are associated with functional impairments in people with schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: emotion identification deficits are associated with functional impairments in people with schizophrenia Article Text Prevalence Review: emotion identification deficits are associated with functional impairments in people with schizophrenia Statistics from

Evidence-Based Mental Health2012

198. Use of benzodiazepines in adults with schizophrenia is associated with increased mortality

Use of benzodiazepines in adults with schizophrenia is associated with increased mortality Use of benzodiazepines in adults with schizophrenia is associated with increased mortality | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Use of benzodiazepines in adults with schizophrenia is associated with increased mortality Article Text Aetiology Use of benzodiazepines in adults with schizophrenia is associated with increased mortality Statistics from Altmetric.com No Altmetric data available for this article. Question Question : Is use

Evidence-Based Mental Health2012

199. Review: maintenance antipsychotics prevent relapse in patients with schizophrenia

Review: maintenance antipsychotics prevent relapse in patients with schizophrenia Review: maintenance antipsychotics prevent relapse in patients with schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu (...) Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: maintenance antipsychotics prevent relapse in patients with schizophrenia Article Text Therapeutics Review: maintenance antipsychotics prevent relapse in patients with schizophrenia Statistics from Altmetric.com No Altmetric data available for this article. Question Question: Are antipsychotics effective in preventing relapse

Evidence-Based Mental Health2012

200. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia (...) in Sweden Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of paliperidone palmitate for patients with schizophrenia, who had experienced two

NHS Economic Evaluation Database.2012